Heme oxygenase-1 (HO-1) has been suggested to be a key neuroprotective enzyme because of its widespread distribution in the brain as well as its strong antioxidative effects. HX106N, a water-soluble botanical formulation, has previously been demonstrated to prevent amyloid b-induced memory impairment and oxidative stress in mice by upregulating HO-1 levels. In this study, the underlying molecular mechanisms of HX106N-induced HO-1 expression were investigated using BV-2 cells, a murine microglial cell line, and primary microglia. Treatment with HX106N induced the expression of HO-1 at the transcriptional level through the stress-responsive element-containing enhancer present in the ho-1 promoter. Nuclear factor E2-related factor 2 (Nrf2) was activated in cells treated with HX106N. The results from knockdown assay showed that small interfering RNA of Nrf2 attenuated HX106N-mediated HO-1 expression. Pharmacological inhibitors of p38 and JNK mitogen-activated protein kinases suppressed the HX106N-mediated induction of HO-1. The NF-kB signaling pathway was activated by HX106N and played a role in HX106Ninduced HO-1 expression. Furthermore, HO-1 and one of its by-products during the enzymatic degradation of heme, CO, were found to be involved in HX106N-mediated suppression of NO production. Taken together, these data indicate that HX106N exerts potent antioxidative effects by increasing the expression of HO-1 through multiple signaling pathways, leading to the suppression of NO production.
Introduction
The level of heme oxygenase-1 (HO-1) has been reported to influence the state and progress of various neurological diseases, including neurodegenerative diseases and ischemic brain diseases. [1] [2] [3] [4] HO-1, one of major isoforms of heme oxygenase in the brain, is a rate-limiting enzyme responsible for catalyzing the degradation of heme to biliverdin, carbon monoxide (CO), and ferrous iron. 5 The expression of HO-1 can be induced specifically in microglia and astrocytes in response to a wide range of stress stimuli. Numerous studies have demonstrated that the induction of HO-1 plays a key role in cellular defense responses through the antiinflammatory and antioxidative activities of its enzymatic by-products as well as through the HO-1 protein itself. [6] [7] [8] [9] [10] In the nervous system, the neuroprotective role of HO-1 has been well documented. Transgenic mice that overexpress HO-1 in the brain are resistant to ischemic brain damage, 11 while HO-1 overexpression protects neurons from various oxidative stimuli, such as glutamate and hydrogen peroxide. 12, 13 Owing to its antioxidative activities and widespread expression in the brain, HO-1 has been proposed as a therapeutic target for several nervous system disorders. 14 The expression of HO-1 is regulated by complex cooperative interactions between various signaling kinases and transcription factors. Mitogen-activated protein kinases (MAPKs) have been reported to play a major role in HO-1 expression, and other kinases, including phosphatidylinositol 3-kinase (PI3K) and protein kinases A and C, might also be involved. 15 Multiple cis-acting elements in the ho-1 promoter play critical roles in transcriptional regulation. In particular, the stress-responsive element (StRE), a 10-bp sequence motif in the E1 and E2 enhancers, has been identified as a dominant cis-element for the induction of ho-1 gene expression. 16, 17 Activating protein-1 (AP-1), composed of homo-and heterodimers from the Jun and Fos families, and nuclear factor E2-related factor 2 (Nrf2) are StRE-binding activating transcription factors for the ho-1 gene. 16, 18 Two potential binding sequences for NF-kB were also identified within the immediate 5 0 flanking region of the human ho-1 gene, but it is currently unclear if these sequences are functional. 19 The consensus NF-kB binding sequence has not been observed in other mammalian ho-1 genes. 19 However, accumulating evidence indicates that NF-kB contributes to HO-1 expression. Several agents, including curcumin, resveratrol, and docosahexaenoic acid, have been reported to induce HO-1 expression through NF-kB. [20] [21] [22] HX106N is a botanical formulation that ameliorates memory impairment in amyloid b peptide-treated mice and generates strong antioxidative and neuroprotective activities, most likely by upregulating HO-1 expression. 23 In the present study, we investigated the molecular mechanisms underlying HX106N-mediated HO-1 expression using BV-2 cells and primary microglial cultures. HX106N induced the expression of ho-1 RNA by activating various transcription factors and signaling molecules such as Nrf2, NF-kB, JNK, and p38 MAPK, all of which are known to be involved in HO-1 expression. HX106N-mediated suppression of nitric oxide (NO) production was inhibited by HO-1specific inhibitors and small interfering RNA (siRNA). Our data suggest that the inhibitory effects of HX106N on NO production most likely resulted from the induction of the ho-1 gene by multiple signaling pathways, which might contribute to the antioxidative activities of HX106N.
Materials and methods
Cell culture and reagents BV-2 cells (a gift from Dr Eui-Ju Choi, Korea University, Korea) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin) at 37 C under 5% CO 2 . Primary cortical microglia were isolated from Institute Cancer Research (ICR) mice on postnatal day 1-3 (P1-3) with a mild trypsinization method as described previously. 24 LPS (Escherichia coli, 0111:B4), SB203580, SP600125, BAY 11-7802, Zinc (II) protoporphyrin-IX (ZnPP), hemoglobin (Hb), and carbon monoxide releasing molecule 3 (CORM-3) were purchased from Sigma (St Louis, MO, USA). PD98059 was purchased from Calbiochem (La Jolla, CA, USA).
Preparation of HX106N
HX106N was prepared from four plants as described previously. 23 
Western blot analysis
After treatment, cells were washed with cold PBS and lysed with phosphosafe extraction buffer (Novagen, Madison, WI, USA). The lysates were then separated by 10% SDS-PAGE and electrophoretically transferred to PVDF membranes. The membranes were incubated with primary antibodies specific for HO-1 (1:4000, Stressgen, Victoria, Canada), Nrf2 (1:500, Santa Cruz Biotechnology, Santa Cruz, CA), c-Jun (1:500, Santa Cruz), p-JNK (1:1000, Cell Signaling, Beverly, MA), JNK (1:1000), p-p38 (1:1000, Cell Signaling), p38 (1:1000, Santa Cruz), p-IKKa/b (1:1:1000, Cell Signaling), IKKa (1:500, Santa Cruz), IkBa (1:500, Santa Cruz), p65 (1:500, Santa Cruz), iNOS (1:1000, BD Biosciences, Franklin Lakes, NJ), Arginase-1 (1:1000, Cell signaling), Arginase-2 (1:500, Santa Cruz), b-actin (1:5000, Sigma), or TFIIB (1:500, Santa Cruz). The membranes were then incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (Sigma) antibodies. The bands were visualized by enhanced chemiluminescence (Millipore, Billerica, MA, USA) using X-ray film, and the band density was quantitated using Image J software.
Northern blot analysis
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The RNA was separated with 1% agarose-formaldehyde gel electrophoresis and transferred to a nylon membrane (Hybond-N, Amersham, Buckinghamshire, UK). The membrane was hybridized with 32 P-labeled mouse HO-1 and GAPDH probes overnight at 68 C. The blot was then washed and exposed to autoradiography film. The band density was measured using Image J software. Specific probes for mouse HO-1 and GAPDH were labeled by random priming using the Klenow fragment of DNA polymerase I (Stratagene, La Jolla, CA, USA) and [a-32 P]dCTP (Perkin Elmer, Norwalk, CT, USA). The PCR primer sequences were as follows: HO-1 (forward, TAC ACA TCC AAG CCG AGA AT; reverse, GTT CCT CTG TCA GCA TCA CC) and GAPDH (forward, ACG GCA AAT TCA ACG GCA CAG; reverse, GGC GGC ACG TCA GAT CC).
Luciferase reporter plasmid assay
Reporter plasmids containing the 15 kb ho-1 promoter (pHO15-Luc), E1 (pE1-Luc), and E1M (pE1M-Luc) sequences were provided by Dr Eun-Hye Joe (Ajou University School of Medicine, Suwon, Korea). Reporter plasmid with five copies of an NF-kB response element (pNF-kB-Luc) was purchased from Promega (Madison, WI, USA). These plasmids encode luciferase as a reporter gene. BV-2 cells were transiently transfected with various reporter plasmids (3 mg) and a b-galactosidase plasmid (1 mg, Invitrogen) using FuGENE6 according to the manufacturer's protocols (Roche, Indianapolis, IN, USA). Twenty-four hours after transfection, the cells were treated with HX106N in the presence or absence of pharmacological inhibitors and incubated for another 9 h. Cell lysates were prepared, and a luciferase activity assay was performed using the Luciferase Reporter kit according to the manufacturer's protocol (Promega) with a microplate luminometer (MicroLumat Plus LB96V, Berthold, Germany). Luciferase activity was normalized to b-gal activity. 
Electrophoretic mobility shift assay (EMSA)
BV-2 cells were treated with HX106N for 3 h and the cells were harvested. The cells were incubated with 200 mL of lysis buffer A (10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT, and protease inhibitor cocktail [Roche]) for 20 min. The same volume of lysis buffer B (lysis buffer A containing 0.5% Nonidet-P40) was added and incubated for an additional 20 min followed by centrifugation. The pellets were washed with 400 mL of lysis buffer A. After centrifugation, the pellets were resuspended in 20 mL of lysis buffer C (10 mM HEPES [pH 7.9], 400 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM DTT, and protease inhibitor cocktail [Roche]) and incubated on ice for 1 h. A centrifugation step generated the nuclear extracts. The binding reaction was performed in binding buffer (Novagen) containing 0.01 unit of poly(dI-dC), 2 mg of salmon sperm DNA, 0.05 pmol [ 32 P]-labeled DNA probe, and 10 mg of nuclear extracts. After incubation for 30 min on ice, the reaction was analyzed on non-denaturing 6% polyacrylamide gels that were electrophoresed using 0.5X TBE buffer (44.5 mM Tris base, 22.3 mM boric acid, and 1 mM EDTA [pH 8.0]). The gels were exposed to autoradiography film at -80 C. Oligonucleotide sequences designed for probe preparation were as follows (the binding motif is underlined): AP-1 (GCTTGATGACTCAGCCGGAA), ARE (TGGGGAACCTGTGCTGAGTCACTGGAG), and NF-kB (AGTTGAGGGGACTTTCCCAGGC). The specificity of the retarded complexes was confirmed by competition with 100-fold excess unlabeled oligonucleotide. For supershift/interference assays, the nuclear extracts were preincubated with 4 mg of anti-Nrf2, c-Jun, or p65 antibody (Santa Cruz) for 30 min on ice before the addition of the probe.
Transfection
The siRNA specific for Nrf2 (siNrf2), c-Jun (sic-Jun), IKKa (siIKKa), HO-1 (siHO-1), and a non-specific control siRNA (siCon; SN-1001) were synthesized by Bioneer (Daejeon, Korea). The siRNA was transfected into BV-2 cells using the Lipofectamine2000 reagent according to the manufacturer's protocol (Invitrogen). After 24 h, the cells were used for assays.
Measurement of NO
The level of NO present in culture supernatants was measured using a NO assay kit according to the manufacturer's instruction (R&D Systems, Minneapolis, MN, USA).
Statistics
The data are presented as the mean AE SD. Significant differences between the experimental groups were analyzed using Student's t-test. P-values less than 0.05 were considered significant.
Results

Effects of HX106N on the expression of HO-1
HO-1 is known to play critical roles in the maintenance of cellular homeostasis under stressful conditions. 15 Our previous study showed that HX106N has antioxidative activity, which coincided with a marked increase in the expression level of HO-1. However, the underlying molecular mechanism remained to be elucidated. In this study, we investigated the mechanism by which HX106N regulates HO-1 expression using BV-2 cells, a murine microglial cell line. First, BV-2 cells were treated with 1 mg/mL HX106N for various time periods, and whole cell lysates were prepared for the detection of HO-1 by Western blot analysis. The amount of HO-1 protein increased 6 h after treatment with HX106N, remained at a high level for 24 h, and then returned to the basal level after 48 h (Figure 1(a) ). The effect on HO-1 was dose dependent, as shown in Figure  1 (b). When the cells were treated with HX106N at a 1 mg/mL concentration for 24 h, the protein level of HO-1 was increased 11-fold ( Figure 1 result was restricted to a particular cell type, primary microglia were isolated from the cortex of P1-P2 mice and treated with 1 mg/mL HX106N for 24 h. When measured by Western blot analysis, treatment with HX106N increased HO-1 expression threefold compared to the control level ( Figure 1(c) ). These data indicated that HX106N could effectively induce HO-1 expression in cells of microglial origin.
Effects of HX106N on ho-1 transcription
Expression of the ho-1 gene is known to be regulated mainly at the transcription level. 15 To investigate the effect of HX106N on ho-1 transcription, BV-2 cells were treated with various concentrations of HX106N for 12 h, and total RNAs were prepared followed by Northern blot hybridization. The basal RNA level of HO-1 was very low but increased substantially after treatment with HX106N in a dose-dependent manner, resulting in an approximately 15fold increase at a 1 mg/mL concentration (Figure 2 (a)).
When the RNA level of HO-1 was measured at earlier time points, 3, 6, and 9 h after treatment with 1 mg/mL HX106N, it was increased by 2.9 -, 6.5 -, and 10.0-fold, compared to untreated cells, respectively (data not shown).
These results indicated that HX106N regulated the expression of HO-1 at the RNA level. The effect of HX106N on the ho-1 promoter was examined using a luciferase reporter plasmid, pHO15-Luc, containing the 15 kb full-length ho-1 promoter sequence. BV-2 cells were transfected with pHO15-Luc and treated with various concentrations of HX106N for 9 h. Treatment with HX106N significantly increased the level of luciferase activity in a dose-dependent manner, and a 27-fold increase was observed at the 1 mg/mL concentration (Figure 2(b) ).
The ho-1 promoter contains multiple copies of the StRE in the region called E1 and E2, which have been shown to be the primary loci responsible for ho-1 transcriptional activation in response to various agents. 15, 25, 26 To test whether these enhancers are also involved in HX106N-mediated ho-1 transcription, BV-2 cells were transfected with the luciferase reporter plasmids containing the wild-type (pE1-Luc) or mutant (pE1M-Luc) E1 enhancer sequence. Treatment with 1 mg/mL HX106N resulted in a 6.9-fold increase in the level of luciferase activity over that of cells transfected with pE1-Luc, while no significant change was found in cells transfected with pE1M-luc ( Figure 2(c) ). These data indicated that HX106N regulated the transcription of ho-1 through the StRE-containing enhancer present in the ho-1 promoter.
Effects of HX106N on Nrf2 and AP-1 activation
Because the StRE is structurally and functionally similar to the antioxidant response element (ARE) and AP-1 binding site, Nrf2 and AP-1 have been proposed to be the major transcription factors regulating the expression of ho-1 in response to various stimuli. 16, 18, 27, 28 Therefore, the effect of HX106N on the activation of Nrf2 and AP-1 was examined by assessing the nuclear accumulation of Nrf2 and c-Jun, a major component of the AP-1 family. BV-2 cells were treated with 1 mg/mL HX106N, and the nuclear proteins were extracted at various time points, followed by Western blot analysis to determine the levels of these two transcription factors. The levels of Nrf2 and c-Jun remained very low or undetectable at all of the time points examined in untreated cells, but a marked increase was observed after 1 h of HX106N treatment and was maintained throughout the experimental time course (Figure 3(a) ).
To verify these results, a gel retardation assay was performed using ARE and AP-1 oligonucleotide probes. BV-2 cells were treated with 1 mg/mL HX106N for 3 h, and nuclear extracts were prepared, followed by EMSA. Treatment with HX106N significantly increased the amount of DNA-protein complex for both probes (Figure  3 (b) and (c)). These complexes were specific because competition with cold oligonucleotide probes decreased the signal. Supershift/interference assays were carried out to test the binding of Nrf2 or c-Jun to ARE or AP-1 oligonucleotides, respectively. In the presence of Nrf2 or c-Jun antibodies, the formation of DNA-protein complex was inhibited (Figure 3 (b) and (c)).
To examine the roles of Nrf2 and AP-1 in the HX106Ninduced HO-1 expression, BV-2 cells were transfected with siRNA specific for Nrf2 (siNrf2), c-Jun (sic-Jun), or a nonspecific siRNA (siControl). Twenty-four hours later, the cells were treated with 1 mg/mL HX106N for 6 h, and whole cell lysates were prepared followed by Western blot analysis. When compared to the case of siControl, siNrf2 and si-cJun transfection downregulated the protein level of Nrf2 and c-Jun by 54 and 62%, respectively ( Figure  3(d) ). The level of HO-1 was greatly increased by HX106N treatment in the cells transfected with siControl, while it was reduced by 40% in those with siNrf2 ( Figure 3(d) ). Sic-Jun transfection affected the basal level of HO-1, but (Figure 3(d) ). Taken together, these data indicated that Nrf2 played a role in the HX106N-mediated induction of HO-1, although both Nrf2 and AP-1 transcription factors were activated by HX106N.
Effect of HX106N on MAPKs activation
MAPKs have been implicated as one of the major regulators of HO-1 expression. [29] [30] [31] To test whether MAPK signaling has any effect on HX106N-mediated HO-1 expression, pharmacological MAPK inhibitors (i.e. JNK: SP600125; p38 MAPK: SB203580; ERK: PD98059) were applied to the cells. When BV-2 cells were treated with different concentrations of SP600125 or SB203580 in the presence of HX106N, the induction of HO-1 protein by HX106N was significantly reduced by 63 and 93%, respectively, in a dose-dependent manner at a 20 mM concentration ( Figure  4(a) ). The HX106N-mediated increase of ho-1 RNA was also attenuated by both inhibitors (data not shown). Treatment with PD98059 had little effect on the level of HO-1 expression, suggesting that JNK and p38 MAPK but not ERK were involved in HX106N-induced HO-1 expression (Figure 4(b) ).
To test the effects of HX106N on the activation of the JNK and p38 pathways, BV-2 cells were treated with 1 mg/mL HX106N, and total proteins were prepared at various time points followed by Western blot analysis. A marked increase in the phosphorylated JNK and p38 levels was observed after 15 min of HX106N treatment, which subsequently decreased over time (Figure 4(c) ). No significant change in the level of total JNK and p38 was observed (Figure 4(c) ). These data indicated that HX106N activated JNK and p38 signaling pathways.
Because MAPKs have been implicated in upstream signaling pathways leading to Nrf2 activation, the JNK and p38 signaling pathways were investigated for involvement in HX106N-mediated Nrf2 activation. BV-2 cells were treated with 20 mM SP600125 or SB203580 in the presence of 1 mg/mL HX106N for 6 h, and the nuclear extracts were isolated and analyzed by Western blot analysis for Nrf2. As shown in Figure 4(d) , HX106N-mediated nuclear accumulation of Nrf2 was not affected by treatment with SP600125 or SB203580.
To confirm the above results, the effect of specific inhibitors of JNK and p38 MAPK (SP600125 and SB203580, respectively) on Nrf2-mediated transcriptional activation was examined using a reporter plasmid containing StRE, pE1-Luc. BV-2 cells transfected with pE1-Luc were treated with respective inhibitors and HX106N for 9 h, and the luciferase activity was measured. Neither SP600125 nor SB203580 affected HX106N-mediated increase of luciferase activity (Figure 4(e) ). These data suggested that JNK and p38 MAPK did not act as an upstream kinase in HX106Nmediated activation of Nrf2.
Effect of HX106N on NF-iB activation
It has been reported that NF-kB is important for HO-1 expression in response to diverse stimuli. 15, 19 To test whether the inhibition of NF-kB activation has any effect on HX106N-induced HO-1 expression, BV-2 cells were treated with different concentrations of a pharmacological inhibitor for IkB kinase (IKK), BAY 11-7082, in the presence of 1 mg/mL HX106N for 24 h. Whole cell lysates were prepared and analyzed to measure the protein level of HO-1 by Western blot analysis. The expression of HO-1 protein was highly increased in the cells treated with HX106N, whereas treatment with BAY 11-7082 decreased the expression by 43 and 70% at 2.5 and 5 mM, respectively ( Figure 5(a) ). The increased RNA level of HO-1 was also reduced by 2.5 mM of BAY 11-7082 to 62% (data not shown). To confirm the above data, siRNA specific for IKKa (siIKKa) was transfected to BV-2 cells. The cells were treated with 1 mg/mL HX106N for 6 h, and total proteins were extracted to measure the levels of IKKa and HO-1 using Western blot analysis. As shown in Figure 5 (b), the protein level of IKKa was greatly reduced by siIKKa transfection. In these siIKKa-transfected cells, HX106N-mediated HO-1 induction was decreased by 54%, as compared to siControltransfected cells ( Figure 5(b) ). These results demonstrated that the activation of NF-kB might contribute to HX106Nmediated HO-1 expression.
To examine the effect of HX106N on the NF-kB signaling pathway, BV-2 cells were treated with 1 mg/mL HX106N, and total proteins were prepared at various time points for the detection of total and phosphorylated forms of IKK and IkB. As shown in Figure 5 (c), IKK phosphorylation was detected 15 min after HX106N treatment and returned to the basal level within 3 h. Consistent with the above results, a significant decrease in the level of IkB was observed between 15 and 30 min of treatment with HX106N ( Figure 5(c) ).
The effect of HX106N on NF-kB activation was assessed by measuring the nuclear accumulation of the NF-kB p65 subunit. Nuclear extracts were prepared from BV-2 cells treated with 1 mg/mL HX106N for the indicated time periods in Figure 5 (d) and subjected to Western blot analysis using an antibody specific for p65. The nuclear level of p65 was very low in the untreated cells but was strongly increased at all time points (1-6 h) ( Figure 5(d) ).
To confirm these observations with a gel retardation assay using an NF-kB oligonucleotide probe, BV-2 cells were treated with 1 mg/mL HX106N for 3 h, and the nuclear protein was extracted, followed by EMSA. The level of DNA-protein complex was very low in untreated cells but was dramatically increased by treatment with HX106N ( Figure 5(e) ). In the supershift/interference assay, addition of an antibody against p65 diminished the upper complex, indicating that the band was indeed the p65 subunit bound to the NF-kB oligonucleotide ( Figure 5(e) ). These results suggested that HX106N induced the activation of NF-kB.
To test whether JNK and p38 MAPK were involved in HX106N-mediated NF-kB activation, BV-2 cells were treated with 20 mM SP600125 or SB203580 in the presence of 1 mg/mL HX106N. Six hours later, nuclear proteins were prepared, and Western blot analysis was performed to determine the level of p65. Treatment with both inhibitors had little effects on the HX106N-induced nuclear accumulation of p65 ( Figure 5(f) ).
It was also investigated whether SP600125 or SB203580 inhibitors have any effect on NF-kB-mediated transcriptional activity. BV-2 cells were transfected with a luciferase plasmid containing five copies of an NF-kB response element (pNF-kB-Luc) and treated with each inhibitor in the presence of 1 mg/mL HX106N for 9 h. The level of luciferase activity was elevated by 3.4-fold after HX106N treatment, while little changes were observed in the cells treated with SP600125 or SB203580 ( Figure 5(g) ). These data suggested that both of JNK and p38 were not associated with NF-kB activation.
Effect of HX106N on LPS-induced NO production
Excessive NO production by iNOS in activated microglia is reported to be a key mediator of oxidative damage in various neurodegenerative diseases. 32 HX106N has previously been shown to inhibit NO production through regulation of iNOS expression. As HO-1 has been reported to regulate the inflammatory response, including NO production, 33, 34 it was investigated if HO-1 affected HX106N-mediated NO suppression. BV-2 cells were incubated with 100 ng/mL LPS for 24 h in the presence or absence of 1 mg/mL HX106N, and the culture supernatants were analyzed with the Griess assay to measure the amount of nitrite, a stable end product of NO. The nitrite level increased up to 28.2 mM in the supernatant from LPS-stimulated cells but was significantly decreased to 7.0 mM after treatment with HX106N ( Figure 6(a) ). When 100 nM ZnPP, a pharmacological inhibitor of HO-1, was added to the cells, the nitrite level increased to 15.3 mM (Figure 6(a) ). Treatment with ZnPP did not affect HX106N-induced RNA expression of HO-1 (Figure 6(b) ).
To test whether ZnPP has any effect on HX106N-suppressed iNOS expression, whole cell lysates were extracted from the same experiments and subjected to Western blot analysis for the detection of iNOS. As shown in Figure 6 (c), treatment with HX106N significantly decreased LPSinduced iNOS expression by 83%, and this inhibition was not affected by ZnPP. These data suggested that HO-1 might not contribute to HX106N-mediated iNOS suppression.
We confirmed the above observation by knockdown of HO-1 using a specific siRNA. BV-2 cells were transfected with siRNA specific for HO-1 (siHO-1) or a non-specific siRNA (siControl) and treated with 1 mg/mL HX106N for 24 h. The Western blot analysis showed that siHO-1 significantly decreased HX106N-induced HO-1 expression, by 58%, whereas siControl had no effect ( Figure 6(d) ).
SiRNA-transfected cells were stimulated with 100 ng/mL LPS in the presence or absence of 1 mg/mL HX106N for 24 h, and the level of nitrite and iNOS expression was measured in the culture supernatant and cellular proteins, respectively. As shown in Figure 6 (e), LPSinduced nitrite production in siHO-1-transfected cells increased by 1.3-fold compared to siControl-transfected cells, although the increase was not statistically significant. When cells were treated with HX106N, the level of nitrite in siHO-1-transfected cells was twofold higher than that in siControl-transfected cells ( Figure 6(e) ). These results confirmed the involvement of HO-1 in HX106N-mediated NO suppression. HX106N-mediated suppression of iNOS expression was not affected by siHO-1 transfection, consistent with the results from ZnPP treatment ( Figure 6(f) ). Primary cultured microglia were also used to test the effects of HX106N on NO production. The cells were stimulated with 100 ng/mL LPS in the presence or absence of 1 mg/mL HX106N and 100 nM ZnPP for 48 h and the culture supernatant was harvested to detect the nitrite level.
Consistent with the results from the BV-2 cells, treatment with HX106N effectively suppressed the increase in the level of nitrite in LPS-stimulated primary microglia, and this suppression was antagonized by ZnPP treatment (Figure 6(g) ). Taken together, HO-1 appears to be involved in the HX106N-mediated inhibition of NO production but not in the control of iNOS expression.
CO, an enzymatic by-product of HO-1 activity, has been known to suppress NO production without affecting the iNOS protein level. 35, 36 Therefore, it was tested whether CO was involved in the HX106N-mediated downregulation of NO. BV-2 cells were incubated with 100 ng/mL LPS in the presence or absence of 1 mg/mL HX106N, 1 mM Hb, a CO scavenger, and 100 mM CORM-3, a CO donor, for 24 h. The supernatant and cell lysates were harvested and used to measure the level of nitrite and iNOS protein, respectively. As expected, Hb attenuated the inhibitory effect of HX106N on LPS-induced NO production, while CORM-3 significantly suppressed the production of NO ( Figure  6(h) ). As shown in Figure 6 (i), the decreased level of iNOS protein by HX106N was not affected by Hb, while CORM-3 also had little effect on LPS-induced iNOS expression. These data indicated that CO is a critical factor for HX106N-mediated NO suppression, but with no effect on iNOS expression. Because arginase, an enzyme that converts L-arginine into L -ornithine and urea, is known to reciprocally regulate NOS activity, 37 it was also investigated whether HX106N has any effect on the level of arginase expression. The expression of both arginase-1 and ariginase-2 was not affected by treatment with HX106N (data not shown).
Discussion
In this report, we demonstrated that HX106N increased the expression of HO-1 and suppressed the production of NO. Various cellular factors appeared to be involved in HX106N-mediated induction of the ho-1 gene, including Nrf2, NF-kB, JNK, and p38 MAPK (Figure 7) .
Nrf2 plays a crucial role in the increased expression of HO-1 by HX106N as evidenced by reduction of HO-1 induction when Nrf2-specific siRNA was used. Nrf2 is normally present in the cytoplasm in a combined form with Keap1 (Kelch-like ECH-associated protein 1) but when Nrf2 and Keap1 dissociate by various stimulations, Nrf2 translocates to the nucleus to activate the expression of a wide range of antioxidant genes. 38, 39 We investigated which signal transduction pathway is used for activation of Nrf2, but had no success thus far. Virtually all kinases previously known to phosphorylate and activate Nrf2 did not seem to be involved in HX106N-mediated induction of HO-1 in the experiments involving the pharmacological inhibitors of MAPKs, PI3K, protein kinase C (PKC), and casein kinase 2 (CK2) (data not shown). Some chemopreventive agents directly oxidize or chemically modify the cysteine thiols of Keap1, leading to the dissociation of Keap1 and subsequent release of Nrf2. 40, 41 Therefore, it is possible that HX106N may contain compound(s) that directly modulate the Nrf2-Keap1 interaction without involving an upstream signaling pathway.
The expression of HO-1 is also reported to be regulated by NF-kB. [20] [21] [22] The activation of this transcription factor was found to be important in HX106N-mediated upregulation of HO-1, as shown in the experiments involving a pharmacological inhibitor or siRNA specific for IKK. Since the functional NF-kB binding site has not been clearly identified in the ho-1 gene, 19 further molecular studies to find the actual binding site for NF-kB that control HX106Ninduced ho-1 gene expression would be of interest.
A variety of kinases have been identified to phosphorylate and activate transcription factors involved in regulation of HO-1 expression. We demonstrated that JNK and p38 MAPK played a role(s) in HX106N-mediated HO-1 induction using a pharmacological inhibitor (SP600125 and SB203580) but could not find the actual transcription factor acting as their downstream mediator. It is likely that other transcription factors participate in HO-1 induction by HX106N, since the ho-1 promoter contains a variety of cis-acting elements, including c-AMP-responsive element (CRE), STAT, and a heat shock element. 15 Both STAT3 and HSF-1 are regulated by JNK, 42, 43 while the activation of CRE-binding protein by p38 MAPK was demonstrated to be involved in HO-1 expression induced by raloxifene, an estrogen receptor modulator. 44 In the case of p38 MAPK, it is also possible that p38 MAPK contributes to HX106Ninduced HO-1 expression without direct effect on transcription factors, because this protein is known to regulate the phosphorylation of TATA-binding protein. 45 HX106N effectively suppressed the production of NO, and HO-1 played an important role in this process through CO generation. However, HO-1 and CO were not involved in HX106N-mediated suppression of iNOS expression. CO is known to inhibit iNOS activity, but not its expression, by interacting with the heme iron moiety of the enzyme. 35, 36 Therefore, it is possible that CO released from HO-1catalyzed reactions may inhibit iNOS activity, resulting in the regulation of NO production by HX106N.
HX106N
Our data indicate that HX106N exhibits antioxidative activity through the induction of the ho-1 gene in microglial cells. Although the active compound(s) in HX106N remain to be identified, we were able to make HX106N containing consistent activities using cell-based bioassays. 23 HX106N prepared as such could reproducibly improve the cognitive functions in the amnesia animal models. 23, 46 Taken together, further in-depth investigations are warranted to test HX106N as a therapeutic agent for various neurodegenerative diseases.
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